Nova Leap Health Corp. Posts Best Financial Performance in Company History with Record Q3 2025 Results

Core Viewpoint - Nova Leap Health Corp. reported record financial results for Q3 2025, achieving significant growth in revenues and Adjusted EBITDA, reflecting strong operational performance and strategic execution [2][4][7]. Financial Performance - Q3 2025 revenues reached $8,264,326, marking a 3% increase from Q2 2025 and a 29% increase from Q3 2024 [2]. - Adjusted EBITDA for Q3 2025 was $670,706, up 16.1% from Q2 2025 and 76.9% from Q3 2024 [4]. - The gross profit margin was 39.6% in Q3 2025, compared to 40.2% in Q2 2025 and 38.0% in Q3 2024 [10]. Record Achievements - The company set nine financial records in Q3 2025, including consolidated revenues, gross margin, and Adjusted EBITDA [5][7]. - Canadian and U.S. operating segments also achieved record revenues, gross margins, and Adjusted EBITDA [5]. Operational Insights - The company has established a new performance benchmark with Adjusted EBITDA averaging over $400,000 quarterly from Q2 2023 to Q1 2025, now reset to higher levels [8]. - The company generated income from operating activities of $418,553 in Q3 2025, an increase from previous quarters [10]. Financial Position - As of September 30, 2025, the company had available cash of $1,571,716 and access to an unutilized revolving credit facility of $1,077,509 [10]. - Total demand loans and promissory notes outstanding were $2,300,800, resulting in a leverage ratio of 1.18 times to trailing twelve-month Adjusted EBITDA [10]. Strategic Focus - The company emphasizes disciplined growth, profitability, and long-term value creation, supported by a strong balance sheet and positive operating cash flow [9][10].